RxDoctor Payments DataLook up a doctor →

Jacquelyn Renneberg, APRN

Acute Care · Shenandoah, TXNPI 1275048118

Payments from drug & device makers

$13,903in general payments, 2019–2025

Across 463 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$2K
  • Abbott$1K
  • Novartis$896
  • Johnson & Johnson$574
  • Impulse Dynamics (USA) Inc.$464
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$3,21423%
  • Food & beverage$10,64977%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,903 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$75,761
Medicare patients
493
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban288$246,289
XareltoRivaroxaban57$56,645
Dofetilide91$9,956
Metoprolol Succinate296$3,126
Flecainide Acetate69$2,799
Valsartan22$1,083
Amiodarone Hcl57$868
Nebivolol Hcl12$630
ClopidogrelClopidogrel Bisulfate52$537
Carvedilol71$471
Metoprolol Tartrate85$409
Warfarin Sodium15$270
Losartan Potassium39$249
Amlodipine Besylate29$165
Propranolol Hcl16$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$246,289288 claims
Johnson & JohnsonXarelto$574$56,64557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.

Other acute care in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →